West Pharmaceutical Services: Takeaways from our fireside chat with WST at 2026 BofA Healthcare Conference

Research evidence excerpt

West Pharmaceutical Services: Takeaways from our fireside chat with WST at 2026 BofA Healthcare Conference

Accessible version

West Pharmaceutical Services

Takeaways from our fireside chat with

WST at 2026 BofA Healthcare Conference

Maintain Rating: BUY | PO: 350.00 USD | Price: 312.07 USD

Fireside chat with CEO and CFO 12 May 2026

We hosted West Pharmaceutical’s (WST) Eric Green (CEO) & Robert McMahon (CFO) for Equity

a fireside chat. The session focused on recently disclosed cybersecurity incident

Michael Ryskin

recovery efforts, HVP-c demand trends, GLP-1 dynamics, and the company’s broader Research Analyst

outlook. Despite near-term operational disruption, mgmt. struck a constructive tone on BofAS +1 646 855 4373

the broader operating backdrop and reiterated confidence in the long-term outlook. We michael.ryskin@bofa.com

maintain our Buy rating. Avantika Dhabaria

Research Analyst

Navigating NT disruption following cybersecurity event BofAS+1 646 743 0170

Mgmt. discussed the cybersecurity-related 8K filed yesterday after the market close avantika.dhabaria@bofa.com

noting the company identified intrusion into its systems on May 4th and proactively shut Alexa Chan Research Analyst

down systems globally to contain the event and conduct a forensic analysis. Mgmt. BofAS

stated that shipping/receiving capabilities and several manufacturing sites were already +1alexa.chan@bofa.com646 855 5636

back online, while additional facilities are being restored through a phased recovery

process focused on system hardening and operational continuity. While mgmt. is not

quantifying potential financial impact, they emphasized that underlying customer

Stock Datademand remains intact and highlighted available flex capacity and potential 24/7

operations to help mitigate disruption.